Cargando…

CA19.9 Response and Tumor Size Predict Recurrence Following Post-neoadjuvant Pancreatectomy in Initially Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma

BACKGROUND: Data on recurrence after post-neoadjuvant pancreatectomy are scant. This study investigated the incidence and pattern of recurrence in patients with initially resectable and borderline resectable pancreatic ductal adenocarcinoma who received post-neoadjuvant pancreatectomy. Furthermore,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maggino, Laura, Malleo, Giuseppe, Crippa, Stefano, Belfiori, Giulio, Nobile, Sara, Gasparini, Giulia, Lionetto, Gabriella, Luchini, Claudio, Mattiolo, Paola, Schiavo-Lena, Marco, Doglioni, Claudio, Scarpa, Aldo, Bassi, Claudio, Falconi, Massimo, Salvia, Roberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Pancreatic Tumors
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9726670/ https://www.ncbi.nlm.nih.gov/pubmed/36227391 http://dx.doi.org/10.1245/s10434-022-12622-w

Ejemplares similares

Importance of Nodal Metastases Location in Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: Results from a Prospective, Lymphadenectomy Protocol
por: Malleo, Giuseppe, et al.
Publicado: (2022)

Long-term Outcomes After Surgical Resection of Pancreatic Metastases from Renal Clear-Cell Carcinoma
por: Malleo, Giuseppe, et al.
Publicado: (2021)

Prognostic Factors After Pancreatectomy for Pancreatic Cancer Initially Metastatic to the Liver
por: Frigerio, Isabella, et al.
Publicado: (2022)

Surgery for Intraductal Papillary Mucinous Neoplasms of the Pancreas: Preoperative Factors Tipping the Scale of Decision-Making
por: Marchegiani, Giovanni, et al.
Publicado: (2022)

Outcomes After Distal Pancreatectomy with Celiac Axis Resection for Pancreatic Cancer: A Pan-European Retrospective Cohort Study
por: Klompmaker, Sjors, et al.
Publicado: (2018)

FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analysis and Systematic Review
por: Eshmuminov, Dilmurodjon, et al.
Publicado: (2023)

Prognostic Impact of Resection Margin Status in Distal Pancreatectomy for Ductal Adenocarcinoma
por: Sahakyan, Mushegh A., et al.
Publicado: (2021)

Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer
por: Alva-Ruiz, Roberto, et al.
Publicado: (2021)

The Sequential Radiographic Effects of Preoperative Chemotherapy and (Chemo)Radiation on Tumor Anatomy in Patients with Localized Pancreatic Cancer
por: Perri, Giampaolo, et al.
Publicado: (2020)

Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis
por: Janssen, Quisette P., et al.
Publicado: (2021)

Robot-Assisted Versus Laparoscopic Distal Pancreatectomy in Patients with Resectable Pancreatic Cancer: An International, Retrospective, Cohort Study
por: Chen, Jeffrey W., et al.
Publicado: (2023)

Predictors for Survival in an International Cohort of Patients Undergoing Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma
por: Korrel, M., et al.
Publicado: (2020)

A Commentary on “Robot-Assisted Versus Laparoscopic Distal Pancreatectomy in Patients with Resectable Pancreatic Cancer: An International, Retrospective, Cohort Study”
por: Xu, Dingwei, et al.
Publicado: (2023)

Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer: An International Multicenter Cohort Study
por: van Veldhuisen, Eran, et al.
Publicado: (2022)

Impact of Borderline Resectability in Pancreatic Head Cancer on Patient Survival: Biology Matters According to the New International Consensus Criteria
por: Anger, Friedrich, et al.
Publicado: (2020)

Impact of Neoadjuvant Therapy in Resected Pancreatic Ductal Adenocarcinoma of the Pancreatic Body or Tail on Surgical and Oncological Outcome: A Propensity-Score Matched Multicenter Study
por: Lof, Sanne, et al.
Publicado: (2019)

Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma Without Increasing Perioperative Toxicity
por: Hill, Colin S., et al.
Publicado: (2022)

Proposal for a New Pathologic Prognostic Index After Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma (PINC)
por: Redegalli, M., et al.
Publicado: (2022)

Race, Insurance, and Sex-Based Disparities in Access to High-Volume Centers for Pancreatectomy
por: Williamson, Catherine G., et al.
Publicado: (2023)

Outcomes of Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma in the Netherlands: A Nationwide Retrospective Analysis
por: de Rooij, Thijs, et al.
Publicado: (2015)

The Prognostic Index Independently Predicts Survival in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Resection
por: Gruber, Elisabeth S., et al.
Publicado: (2020)

Resected Early-Onset Pancreatic Cancer: Practices and Outcomes in an International Dual-Center Study
por: Leonhardt, Carl-Stephan, et al.
Publicado: (2022)

Conditional Survival After Resection for Pancreatic Cancer: A Population-Based Study and Prediction Model
por: Latenstein, Anouk E. J., et al.
Publicado: (2020)

Short- and Long-Term Outcomes of Pancreatic Cancer Resection in Elderly Patients: A Nationwide Analysis
por: Henry, Anne Claire, et al.
Publicado: (2022)

More is More? Total Pancreatectomy for Periampullary Cancer as an Alternative in Patients with High-Risk Pancreatic Anastomosis: A Propensity Score-Matched Analysis
por: Hempel, Sebastian, et al.
Publicado: (2021)

Risk Factors, Management, and Outcome of Gastric Venous Congestion After Total Pancreatectomy: An Underestimated Complication Requiring Standardized Identification, Grading, and Management
por: Stoop, Thomas F., et al.
Publicado: (2023)

What Should Guide the Performance of Venous Resection During Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma with Venous Contact?
por: Navez, Julie, et al.
Publicado: (2021)

Development of a Biomarker-Based Scoring System Predicting Early Recurrence of Resectable Pancreatic Duct Adenocarcinoma
por: Ishido, Keinosuke, et al.
Publicado: (2021)

Preoperative Neutrophil-Lymphocyte and Lymphocyte-Monocyte Ratios Reflect Immune Cell Population Rearrangement in Resectable Pancreatic Cancer
por: Sierzega, Marek, et al.
Publicado: (2016)

How to Approach Para-Aortic Lymph Node Metastases During Exploration for Suspected Periampullary Carcinoma: Resection or Bypass?
por: Pranger, Bobby K., et al.
Publicado: (2020)

Nationwide Validation of the 8th American Joint Committee on Cancer TNM Staging System and Five Proposed Modifications for Resected Pancreatic Cancer
por: Schouten, Thijs J., et al.
Publicado: (2022)

Recurrence of Pancreatic Neuroendocrine Tumors and Survival Predicted by Ki67
por: Genç, C. G., et al.
Publicado: (2018)

Nationwide Impact of Centralization, Neoadjuvant Therapy, Minimally Invasive Surgery, and Standardized Pathology Reporting on R0 Resection and Overall Survival in Pancreatoduodenectomy for Pancreatic Cancer
por: Augustinus, Simone, et al.
Publicado: (2023)

Reply to: Letter to the Editor: More is More? Total Pancreatectomy for Periampullary Cancer as an Alternative in Patients with High-Risk Pancreatic Anastomosis: A Propensity Score-Matched Analysis, by Marchegiani, Giovanni et al.
por: Hempel, Sebastian, et al.
Publicado: (2022)

Is Laparoscopic Liver Resection Safe and Comparable to Open Liver Resection for Hepatocellular Carcinoma?
por: Nguyen, Kevin Tri, et al.
Publicado: (2009)

Long-Term Outcomes of Tuberous Sclerosis Complex-Associated Non-functional Pancreatic Neuroendocrine Tumors: Should We Be More Conservative?
por: Arya, Shahrzad, et al.
Publicado: (2023)

Outcomes and Risk Score for Distal Pancreatectomy with Celiac Axis Resection (DP-CAR): An International Multicenter Analysis
por: Klompmaker, Sjors, et al.
Publicado: (2019)

Adjuvant Chemoradiation for Pancreatic Adenocarcinoma: The Johns Hopkins Hospital—Mayo Clinic Collaborative Study
por: Hsu, Charles C., et al.
Publicado: (2010)

Challenges in the Study of Adjuvant Chemoradiation After Pancreaticoduodenectomy
por: Crane, Christopher H., et al.
Publicado: (2009)

Skeletal Muscle Quality is Associated with Worse Survival After Pancreatoduodenectomy for Periampullary, Nonpancreatic Cancer
por: Van Rijssen, L. B., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ch4116dab2or71ef3a9rd18ob1